Article

Standardizing NfL testing: Why we need cross-platform comparability in multiple sclerosis care

Published on 17 Nov, 2026 | 9 min read
Illustration of two healthcare professionals in lab coats connecting two puzzle pieces, symbolizing standardized NfL testing.

Key takeaways

  • Blood NfL testing may reveal neuroaxonal injury before disease activity becomes visible through conventional monitoring
  • NfL shows promise as a complementary biomarker alongside MRI, clinical assessment, and other patient information to optimize MS management
  • Differences among assays, reference ranges, antibodies, and reporting methods currently limit the comparability of NfL results

More than three million people globally are living with multiple sclerosis (MS), a chronic, neuroinflammatory, and degenerative condition that causes progressive damage to the nervous system.1,2 Neurological damage begins early, driving disease progression often before visible symptoms emerge, meaning early detection and intervention are critical to ensure the best outcome for patients.3,4 Existing standard of care tools are costly, time-consuming, and lack the ability to detect subtle but significant disease progression.3,5 There is a need for accurate, objective, and accessible measures of disease activity and progression in MS.

Blood neurofilament light chain (NfL) testing could give clinicians a more timely view of neuroaxonal injury in people with MS, complementing MRI and clinical assessment between scheduled visits.6,7 Elevated blood NfL levels have been associated with disease activity, relapse risk, and treatment response.6,8-10 However, NfL is not specific to MS, and results can vary according to the assay, patient age, body mass index (BMI), and comorbidities.3,4,11-13

Moving NfL testing from research into routine care will require an industry-wide effort to develop comparable measurements across platforms, certified reference materials, validated reference ranges, and clear guidance for clinical interpretation.5

Why MS care needs more timely measures of disease activity

Traditionally, treatment decisions for MS are guided by MRI scans, combined with clinical assessments.3 While MRI scans are excellent for detecting lesions within the brain, the damage has often already occurred by the time they present, offering only a retrospective view of MS activity.3,6 In addition, the cost of running MRI scans is one of the most significant burdens in MS care, impacting both healthcare systems and patient quality of life. Because MS requires regular and ideally frequent monitoring to track disease progression and treatment efficacy, these compounding financial and time costs present a major challenge. Patients often face long wait times to secure an MRI slot, which can delay critical interventions.8 In areas with limited resources, this can be especially challenging.5,11

Recent advancements in fluid biomarker research present an opportunity to improve monitoring of disease activity and treatment response by measuring subclinical neuroaxonal damage.12-14 In conjunction with existing diagnostic tools, real-time insights on MS disease activity can now be determined via a blood test, most commonly measuring neurofilament light chain NfL in serum. This minimally invasive test helps to bridge the gap between infrequent MRI scans and provides an objective, quantitative, and accessible additional clinical tool for clinicians to optimize patient management.7,11,12

What NfL can reveal about disease activity in MS

NfL is a marker of neuroaxonal injury that can be measured in cerebrospinal fluid (CSF) and blood. Under healthy conditions, low concentrations of NfL are released into the CSF and then normally detectable in blood. NfL concentrations generally increase with age and are also affected by other physiological factors. However, in response to neuroaxonal injury, NfL levels increase proportionally to the degree of damage, making NfL an indicator of ongoing neuronal damage.7,8,12 

Consequently, abnormally elevated NfL concentrations can be measured in CSF and blood in a range of acute and chronic neurological disorders, including MS.12 Blood NfL, particularly serum NfL in much of the published MS evidence, has been associated with active relapses and MRI inflammatory activity.8-10,12 NfL levels can also provide insights before MRI scans, detecting neuronal damage due to inflammation up to five months before it is visible on MRI.3,7 Regular measurement of serum NfL levels could provide an objective, quantitative measure of recent neuroaxonal injury, offering a potential marker of real-time disease activity in disorders such as MS.6 Therefore, blood NfL testing has the potential to allow healthcare providers to adopt a more proactive approach and optimize patient management.6,7 However, while high NfL levels in MS can give insights into ongoing or imminent disease activity and flag the need for additional assessments, they cannot guide patient management decisions in isolation and are most useful in the context of other clinical and imaging evaluations.5,6,11

The potential role of NfL in MS management

The ability to monitor NfL using a blood sample means it can be integrated across clinical practice from diagnosis to treatment adjustment. During the initial evaluation of MS, NfL levels may provide an early indication of subclinical disease activity and future risk, with study data showing that serum NfL levels rise by an average of ~32% in the window just prior to, or during, the emergence of new MRI lesions.7,11,12

Clinical evidence indicates that there may also be promising applications in the prognosis and monitoring of MS disease activity. Several studies have demonstrated a correlation between increased blood NfL levels and a risk of clinical relapse, and there is supportive clinical data for the use of NfL in monitoring treatment response.6,7,9,12,13 Historically, patients have been put on a stepwise therapy that involves starting with lower-efficacy medications and progressively escalating to higher-efficacy drugs if the patient does not respond adequately or symptoms worsen.7,10,12 While not sufficient in isolation, regular serum neurofilament light chain (sNfL) assessments can support clinicians to evaluate treatment efficacy and identify suboptimal response, adding additional information to treatment decisions. A decline in serum NfL may support other evidence of treatment response, while persistently elevated or rising levels may warrant further clinical assessment. High on-treatment NfL levels indicate a poor response and are associated with disability progression; therefore, in the context of other clinical and imaging assessments, action may be necessary to escalate treatment.5-7

Taken together, current evidence points to several potential roles for blood NfL across MS care. Each application also has limitations that must be considered when interpreting results.

Clinical need

Potential contribution of blood NfL in MS

Important limitation

Identifying neuroaxonal injury

May provide a quantitative indication of recent neuronal damage4,6,7,9,10,12

Elevated NfL is not specific to MS, and possible physiological confounders and comorbidities must be accounted for when interpreting the results3-7,11,12

Monitoring disease activity

May complement MRI findings and clinical assessment3,5-7,10-12

Results must not replace MRI and clinical assessments and must not be interpreted in isolation, but alongside other patient information3,5-7,11,12

Assessing treatment response

Changes in NfL may provide additional evidence of response or continuing disease activity6-8,12

Clinically actionable thresholds require further validation and standardization4,6-8,11-13

Monitoring between MRI scans

Blood testing could provide information at more frequent intervals3,5-7

NfL cannot identify the location or cause of neuronal injury3-6,9-12

Supporting longitudinal care

Comparable results could help clinicians follow changes over time using quantitative measures 6,7,12

Differences among assays often complicate comparisons, for example, when patients change providers 4,6,7

Patient stratification and prognostication

Baseline and longitudinal sNfL levels correlate directly with the risk of upcoming clinical relapses and radiological activity6-8,12-14

No universal, platform-independent threshold of prognostic value4,6-8

Table 1. Clinical applications and diagnostic limitations of blood NfL

What currently limits the routine clinical use of NfL testing in MS?

The value of NfL as a biomarker in MS is more and more recognized based on mounting evidence, and the clinical implementation of NfL is rapidly progressing driven by exciting technological innovations. While interpreting results requires accounting for broader clinical contexts, recent advancements have significantly enhanced the ability to measure NfL with high analytical precision.3,4,6,7,11-14

Several testing platforms have been developed to meet this need.4,7,13 The advent of single-molecule array (Simoa®) technology represents a major milestone, enabling the precise detection of low-concentration NfL in the blood.4,7,9,11-14 Furthermore, overcoming the limitation in throughput, the development of ECLIA (electrochemiluminescence immunoassay) and CLIA (chemiluminescent immunoassay) tests allows high sensitivity, specificity, and scalability for broader clinical integration.4,7,13,14 However, several gaps limit routine implementation.

Results are not yet fully comparable across testing platforms

While NfL results from different assays or platforms strongly correlate and reflect the same underlying neuroaxonal damage, they are numerically not comparable.4,7,13,14 The difference in absolute values is due to two primary factors: a current lack of certified reference material (CRM) for NfL, and the use of different antibodies that target distinct epitopes on the protein.4,7,13

Because various platforms use different scales and antibodies that bind to different sites, numerical results vary depending on the specific assay being used and are not directly interchangeable. This lack of standardization between assays can have a direct impact on patient care as switching platforms mid-monitoring can mimic a false biological signal. For example, if a patient moves or changes providers, their NfL results may not be comparable between their new and old treatment providers, disrupting their continuum of care. International position papers (including CMSC/Freedman et al. 2024 and EAN/Furlan et al. 2026) mandate that serial longitudinal monitoring for an individual patient must remain on the exact same assay platform and laboratory. If a platform switch is unavoidable, clinicians must re-establish a new baseline rather than comparing raw numbers directly.5-7,13

Age, BMI, and comorbidities can affect interpretation

There are also several confounding factors that must be taken into consideration when interpreting results due to their impact on blood NfL concentrations, including age, body mass index (BMI), and comorbidities such as cardiovascular disease or diabetes.6,7 A patient over the age of 50, for example, is naturally expected to have a higher serum NfL level compared to a younger patient, so this must be taken into account when analyzing results.5

Age-adjusted percentiles and z-scores play a crucial role in standardizing NfL test interpretation by normalizing raw biomarker values against a healthy reference population. This approach accounts for physiological differences and enables clinicians to more consistently evaluate neuroaxonal injury in MS and track longitudinal changes.5-7

In addition, standardized scores can provide clinicians with a common interpretative framework as NfL results also depend on the analytical system used.3,4,6,7,14 When assay-specific reference populations are available, reporting an individual's result relative to the reference distribution facilitates interpretation within that assay's validated framework.6,7,14 Importantly, however, normalization should not be confused with complete standardization.4,7 Reference models are dependent on the assay, specimen type, and reference population from which they were derived.4,6,7,14 A percentile or z-score generated using one assay should not automatically be assumed equivalent to the same percentile generated using another platform.6,7,13 These elements complicate the use of NfL for doctors who need to be confident in their clinical decision-making.5,7

How standardization could support the clinical adoption of NfL

The principal barrier to routine NfL use is not the ability to detect the biomarker, but the ability to interpret results consistently across methods, laboratories, and patient populations. The technology is available, but currently, clinicians may not feel confident in interpreting the data they receive. If challenges can be overcome, NfL has the potential to revolutionize how we monitor MS and judge if treatments are working.

A certified reference material would align the medical industry and their respective tests on the same reference material. With this, the inter-assay variability would decrease, and a better comparability of test results may help to support doctors in disease detection and treatment.4,5,7,13

The standardization of methodologies would similarly help reduce variability to allow for confident and consistent patient care.4-6,13 Determining cut-offs and guidelines for therapeutic decisions would also be key in establishing the role of NfL throughout the patient journey.5,7,12

Industry-wide collaboration is essential for harmonization

As such, the Consortium of Multiple Sclerosis Centers (CMSC) has highlighted an urgent need for standardization across laboratories and platforms, calling for manufacturers of assays and vendors to work together towards this.5

If this can be achieved, it will assist clinicians with interpretation and enable an integrated approach utilizing blood NfL measurement as a supportive tool alongside MRI assessment and clinical visits. This combination could enable early detection of disease activity, ultimately improving monitoring and therapeutic decision-making to have a genuine impact on the lives of people living with MS.

Email Icon

Get our latest insights

Join our community and stay up to date with the latest laboratory innovations and insights.

Contributors

Headshot of Anja Weidmann

Anja Weidmann, M.Sc.

Product Owner, Assay Development, at Roche Diagnostics

Anja Weidmann works as a Product Owner within Personalized Healthcare Solutions at Roche Diagnostics, specializing in assay development on the Elecsys platform. Holding a Master of Science in Bioengineering and Biotechnology, Anja brings ten years of R&D experience at Roche. Prior to transitioning to Diagnostics four years ago, she spent six years in Pharma Research and Early Development (pRED). In her current role, Anja directs the design and implementation of innovative in vitro diagnostic assays to advance personalized healthcare.

Headshot of Assunta Senatore

Assunta Senatore, PhD

Global Medical Affairs Leader Neurology, MS, at Roche Diagnostics

Assunta Senatore works in Global Medical Affairs for Neuroscience at Roche Diagnostics, with a focus on multiple sclerosis. In this role, she supports medical strategy for neurological biomarkers, including neurofilament light chain (NfL), driving evidence generation projects, external scientific collaborations, and medical education.
 

Trained as a neuroscientist, Assunta holds a PhD in Life Sciences and has more than 10 years of experience in translational neuroscience research, with a particular focus on neurodegenerative diseases and a track record of scientific publications in high-impact journals. She subsequently transitioned to the pharmaceutical industry, where she has held global medical affairs roles in different therapy areas.
 

Her work has focused on translating scientific and clinical evidence into medical strategies that can support better disease assessment and patient management, with her current work centered on advancing the understanding and appropriate use of biomarkers in neurological diseases.

Explore articles from our community

Join the LabLeaders community

Effective laboratory leadership requires a clear view of how laboratories must change to meet the modern demands of healthcare.

With peer-to-peer insights and expert perspectives, LabLeaders offers a deep dive into emerging technologies, best practices for managing lab quality and efficiency, practical guides for evolving diagnostic practices, and more.

Subscribe to our newsletter and discover the latest innovations that can transform your lab.

References

  1. Weinstock-Guttman B, et al. Predicting Long-term Disability in Multiple Sclerosis: A Narrative Review of Current Evidence and Future Directions. Int J MS Care. 2022;24(4):184-188.
  2. King R, et al. Global prevalence of multiple sclerosis surpasses 3 million: 2024 update of the Multiple Sclerosis International Federation Atlas of MS. Mult Scler. 2026;0(0).
  3. Monreal E, et al. Value contribution of blood-based neurofilament light chain as a biomarker in multiple sclerosis using multi-criteria decision analysis. Front Public Health. 2024;12:1397845.
  4. La Civita E, et al. Advancing Clinical Use of Neurofilament Light Chain: Translational Insights From Research to Routine Practice. Biomark Insights. 2025;20:1-10.
  5. The Consortium of Multiple Sclerosis Centres. Best Practices consensus paper. [Internet; cited Sept 26] Available from: https://www.mscare.org/best-practices-guideline-on-the-use-of-neurofilament/
  6. Freedman MS, et al. Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management. EBioMedicine. 2024;101:104970.
  7. Furlan R, et al. Translating neurofilament light chain testing into clinical practice: a multidisciplinary implementation roadmap. Clin Chem Lab Med. 2026;64(9):1904-1918.
  8. Bar-Or A, et al. Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials. EBioMedicine. 2023;93:104662.
  9. Disanto G, et al. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017;81:857-70.
  10. Novakova L, et al. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology. 2017;89:2230-7.
  11. Thebault S, et al. Serum Neurofilament Light Chain Measurement in MS: Hurdles to Clinical Translation. Front Neurosci. 2021;15:654942.
  12. Bittner S, et al. The potential of serum neurofilament as biomarker for multiple sclerosis. Brain. 2021;144:2954-63.
  13. Booth RA, et al. Validation and generation of age-specific reference intervals for a new blood neurofilament light chain assay. Clin Chim Acta. 2025;577:120447.
  14. Zondra Revendova K, et al. Comparison of Simoa, high-sensitivity ELISA, and CLIA for serum neurofilament light chain quantification in multiple sclerosis. Sci Rep. 2025;15:41871.